サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：デジタルバイオマーカー市場- 製品タイプ別、ソリューション目的別、バイオマーカータイプ別、治療分野別、ビジネスモデル別、主要地域別：業界動向と世界の予測
市場調査レポート
商品コード
1471915

デジタルバイオマーカー市場- 製品タイプ別、ソリューション目的別、バイオマーカータイプ別、治療分野別、ビジネスモデル別、主要地域別：業界動向と世界の予測

Digital Biomarkers Market - Distribution by Type of Product, Purpose of Solution, Type of Biomarker, Therapeutic Area, Business Model and Key Geographical Regions : Industry Trends and Global Forecasts
出版日: | 発行: Roots Analysis | ページ情報: 英文 369 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
デジタルバイオマーカー市場- 製品タイプ別、ソリューション目的別、バイオマーカータイプ別、治療分野別、ビジネスモデル別、主要地域別：業界動向と世界の予測
出版日: 2024年04月09日
発行: Roots Analysis
ページ情報: 英文 369 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

デジタルバイオマーカーの市場規模は、2024年に55億5,000万米ドルになるとみられ、予測期間の2024年～2035年のCAGRは18.5％になると予測されています。

個人の健康データを手作業で追跡する従来のアプローチには、重要な健康情報の評価の遅れ、エラーの発生しやすさ、時間とコストのかかるプロセス、健康記録の紛失や破損のリスクなど、数多くの課題があります。これらの要因は、特に高齢化社会におけるタイムリーな治療の妨げとなります。憂慮すべきことに、病院患者の65％、急性期治療後の患者の90％以上が、4～8時間ごとにバイタルと患者固有のパラメーターの手動モニタリングを受けていると推定されています。その結果、遠隔医療が脚光を浴び、デジタルツールを活用して遠隔診察やサービスを提供するようになっています。特筆すべきは、デジタルヘルス技術によって患者の継続的なモニタリングが可能になり、ヘルスケア従事者は個々の患者のベースラインの変化を迅速に追跡できるようになったことです。

さらに、継続的モニタリングシステムの導入により、有害事象や病院の再入院が大幅に減少することが証明されています。デジタルバイオマーカーとデジタル治療薬という急成長中の分野は、広範なデジタル・ヘルス市場の不可欠な構成要素です。さらに、世界保健機関（WHO）によると、2030年までに世界人口の6分の1が60歳以上の高齢者となります。その結果、早期段階で積極的に症状を発見することは、待ち時間が長くなって重症化した患者を治療するよりも直感的に優れています。早期介入を伴う継続的な症状追跡は、患者のQOLの目覚ましい改善につながるだけでなく、ヘルスケアコストの削減にもつながることが研究で実証されています。

ヘルスケア業界におけるデジタル化の高まりは、体内のバイオマーカーを介した医療情報の生成、収集、追跡が可能ないくつかのデジタルソリューションの開発に拍車をかけています。バイオマーカー用デジタルソリューションとは、スマートフォン、センサー、ウェアラブルデバイスなど、血圧、感情的健康状態、心拍数、グルコースレベル、身体活動、呼吸機能、睡眠パターンなどの生理学的、行動学的、生体データを測定・定量化するデジタル機器と定義されます。これらの高度なソリューションは、個人の健康状態をリアルタイムでモニタリングすることを可能にし、特に慢性疾患管理において、ウェルネス活動への積極的な参加を促し、個々のデータに基づいて治療を調整することで個別化ヘルスケアを可能にします。慢性疾患の有病率の上昇、遠隔患者モニタリングの重視の高まり、技術の継続的な進歩により、デジタルバイオマーカー市場は当面成長する見込みです。

当レポートでは、世界のデジタルバイオマーカー市場について調査し、市場の概要とともに、製品タイプ別、ソリューション目的別、バイオマーカータイプ別、治療分野別、ビジネスモデル別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 序文

第2章 調査方法

第3章 経済およびその他のプロジェクト特有の考慮事項

第4章 エグゼクティブサマリー

第5章 イントロダクション

第6章 市場情勢

  • 章の概要
  • デジタルバイオマーカーソリューション：市場情勢
  • デジタルバイオマーカーソリューション：開発者の情勢

第7章 製品競合分析

  • 章の概要
  • 前提と主要なパラメータ
  • 調査手法
  • デジタルバイオマーカーソリューション：製品競合分析

第8章 企業プロファイル：デジタルバイオマーカーソリューション開発企業

第9章 パートナーシップとコラボレーション

  • 章の概要
  • パートナーシップモデル
  • デジタルバイオマーカーソリューション：パートナーシップとコラボレーション

第10章 資金調達と投資

  • 章の概要
  • 資金調達モデル
  • デジタルバイオマーカーソリューション：資金調達と投資

第11章 世界的出来事の分析

第12章 特許分析

第13章 大手製薬会社の取り組み

第14章 市場への影響分析：促進要因、抑制要因、機会、課題

  • 章の概要
  • 市場の促進要因
  • 市場の抑制要因
  • 市場の機会
  • 市場の課題
  • 結論

第15章 世界のデジタルバイオマーカーソリューション市場

第16章 デジタルバイオマーカーソリューション市場、製品タイプ別

第17章 デジタルバイオマーカーソリューション市場、ソリューション目的別

第18章 デジタルバイオマーカーソリューション市場、バイオマーカータイプ別

第19章 デジタルバイオマーカーソリューション市場、治療分野別

第20章 デジタルバイオマーカーソリューション市場、ビジネスモデル別

第21章 デジタルバイオマーカーソリューション市場、主要地域別

第22章 結論

第23章 エグゼクティブインサイト

第24章 付録1：表形式のデータ

第25章 付録2：企業および組織の一覧

図表

List of Tables

  • Table 5.1 Key Advantages and Limitations for Digital Biomarkers
  • Table 6.1 Digital Biomarker Solutions: Overall Market Landscape
  • Table 6.2 Digital Biomarker Solutions: Information on Status of Development, Approving Authority, Launch Data and Purpose of Biomarker Solutions
  • Table 6.3 Digital Biomarker Solutions: Information on Target Indication, Target Therapeutic Area, Target Population and Target Segment
  • Table 6.4 Digital Biomarker Solutions: Information on Solution Specifications, End-user, Clinical Validation and AI Integration
  • Table 6.5 Digital Biomarker Solutions: Developers Landscape
  • Table 8.1 Players Developing Digital Biomarker Solutions: List of Companies Profiled
  • Table 8.2 BioSensics: Company Snapshot
  • Table 8.3 BioSensics: Digital Biomarker Solutions Portfolio
  • Table 8.4 BioSensics: Recent Developments and Future Outlook
  • Table 8.5 Eyenuk: Company Snapshot
  • Table 8.6 Eyenuk: Digital Biomarker Solutions Portfolio
  • Table 8.7 Eyenuk: Recent Developments and Future Outlook
  • Table 8.8 Quibim: Company Snapshot
  • Table 8.9 Quibim: Digital Biomarker Solutions Portfolio
  • Table 8.10 Quibim: Recent Developments and Future Outlook
  • Table 8.11 Feel Therapeutics: Company Snapshot
  • Table 8.12 Feel Therapeutics: Digital Biomarker Solutions Portfolio
  • Table 8.13 Feel Therapeutics: Recent Developments and Future Outlook
  • Table 8.14 AliveCor: Company Snapshot
  • Table 8.15 AliveCor: Digital Biomarker Solutions Portfolio
  • Table 8.16 AliveCor: Recent Developments and Future Outlook
  • Table 8.14 AliveCor: Company Snapshot
  • Table 8.15 AliveCor: Digital Biomarker Solutions Portfolio
  • Table 8.16 AliveCor: Recent Developments and Future Outlook
  • Table 8.17 BACtrack: Company Snapshot
  • Table 8.18 BACtrack: Digital Biomarker Solutions Portfolio
  • Table 8.19 Empatica: Company Snapshot
  • Table 8.20 Empatica: Digital Biomarker Solutions Portfolio
  • Table 8.21 Empatica: Recent Developments and Future Outlook
  • Table 8.22 icometrix: Company Snapshot
  • Table 8.23 icometrix: Digital Biomarker Solutions Portfolio
  • Table 8.24 icometrix: Recent Developments and Future Outlook
  • Table 8.25 Biogen: Company Snapshot
  • Table 8.26 Biogen: Digital Biomarker Solutions Portfolio
  • Table 8.27 Biogen: Recent Developments and Future Outlook
  • Table 8.28 Acculi Labs: Company Snapshot
  • Table 8.29 Acculi Labs: Digital Biomarker Solutions Portfolio
  • Table 8.30 IXICO: Company Snapshot
  • Table 8.31 IXICO: Digital Biomarker Solutions Portfolio
  • Table 8.32 Kinsa: Company Snapshot
  • Table 8.33 Kinsa: Digital Biomarker Solutions Portfolio
  • Table 8.34 Progentec Diagnostics: Company Snapshot
  • Table 8.35 Progentec Diagnostics: Digital Biomarker Solutions Portfolio
  • Table 8.36 Vocalis Health: Company Snapshot
  • Table 8.37 Vocalis Health: Digital Biomarker Solutions Portfolio
  • Table 8.38 Kontigo Care: Company Snapshot
  • Table 8.39 Kontigo Care: Digital Biomarker Solutions Portfolio
  • Table 8.40 Koneksa Health: Company Snapshot
  • Table 8.41 Koneksa Health: Digital Biomarker Solutions Portfolio
  • Table 8.42 ActiGraph: Company Snapshot
  • Table 8.43 ActiGraph: Digital Biomarker Solutions Portfolio
  • Table 8.44 BioSerenity: Company Snapshot
  • Table 8.45 BioSerenity: Digital Biomarker Solutions Portfolio
  • Table 8.46 ATCOR: Company Snapshot
  • Table 8.47 ATCOR: Digital Biomarker Solutions Portfolio
  • Table 8.48 iMediSync: Company Snapshot
  • Table 8.49 iMediSync: Digital Biomarker Solutions Portfolio
  • Table 11.1 Digital Biomarker Solutions: List of Global Events
  • Table 11.3 Global Events Analysis: Information on Name of Speakers and their Designations
  • Table 9.1 Digital Biomarker Solutions: List of Partnerships and Collaborations, Pre-2019-2024
  • Table 10.1 Digital Biomarker Solutions: List of Funding and Investments, Pre-2018-2024
  • Table 11.1 Digital Biomarker Solutions: List of Global Events
  • Table 11.2 Global Events Analysis: Information on Name of Speakers and their Designations
  • Table 12.1 Patent Analysis: Top CPC Sections
  • Table 12.2 Patent Analysis: Top CPC Symbols
  • Table 12.3 Patent Analysis: List of Top CPC Codes
  • Table 12.4 Patent Analysis: Summary of Benchmarking Analysis
  • Table 12.5 Patent Analysis: Categorization based on Weighted Valuation Scores
  • Table 12.6 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
  • Table 23.1 Acculi Labs: Company Snapshot
  • Table 23.2 IXICO: Company Snapshot
  • Table 23.3 Tilak Healthcare: Company Snapshot
  • Table 23.4 Vocalis Health: Company Snapshot
  • Table 24.1 Digital Biomarker Solutions: Distribution by Type of Product
  • Table 24.2 Digital Biomarker Solutions: Distribution by Type of Digital Biomarker Solution
  • Table 24.3 Digital Biomarker Solutions: Distribution by Type of Biomarker
  • Table 24.4 Digital Biomarker Solutions: Distribution by Status of Development
  • Table 24.5 Digital Biomarker Solutions: Distribution by Type of Biomarker and Status of Development
  • Table 24.6 Digital Biomarker Solutions: Distribution by Purpose of Digital Biomarker Solution
  • Table 24.7 Digital Biomarker Solutions: Distribution by Target Therapeutic Area
  • Table 24.8 Digital Biomarker Solutions: Distribution by Type of Biomarker and Target Therapeutic Area
  • Table 24.9 Digital Biomarker Solutions: Distribution by Target Population
  • Table 24.10 Digital Biomarker Solutions: Distribution by End-user
  • Table 24.11 Digital Biomarker Solutions: Distribution by Availability of Clinical Validation
  • Table 24.12 Digital Biomarker Solutions: Distribution of Clinically Validated Solutions by Target Therapeutic Area
  • Table 24.13 Digital Biomarker Solutions: Distribution by Availability of AI Integration
  • Table 24.14 Digital Biomarker Solution Developers: Distribution by Year of Establishment
  • Table 24.15 Digital Biomarker Solution Developers: Distribution by Company Size
  • Table 24.16 Digital Biomarker Solution Developers: Distribution by Location of Headquarters (Region)
  • Table 24.17 Digital Biomarker Solution Developers: Distribution by Location of Headquarters (Country)
  • Table 24.18 Digital Biomarker Solution Developers: Distribution by Company Size and Location of Headquarters
  • Table 24.19 Most Active Players: Distribution by Number of Digital Biomarker Solutions Developed
  • Table 24.20 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2019 - 2024
  • Table 24.21 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 24.22 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Table 24.23 Partnerships and Collaborations: Distribution by Type of Biomarker
  • Table 24.24 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Biomarker
  • Table 24.25 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Table 24.26 Partnerships and Collaborations: Distribution by Type of Partnership and Therapeutic Area
  • Table 24.27 Partnerships and Collaborations: Distribution by Type of Partner
  • Table 24.28 Most Active Players: Distribution by Number of Partnerships
  • Table 24.29 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
  • Table 24.30 Partnerships and Collaborations: International and Local Deals
  • Table 24.31 Funding and Investments: Cumulative Year-wise Trend of Funding Instances, Pre-2018-2024
  • Table 24.32 Funding and Investments: Cumulative Year-wise Trend of Amount Invested, Pre-2018-2024
  • Table 24.33 Funding and Investment: Distribution by Type of Funding
  • Table 24.34 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
  • Table 24.35 Funding and Investments: Distribution by Type of Biomarker
  • Table 24.36 Funding and Investments: Distribution by Therapeutic Area
  • Table 24.37 Leading Investors: Distribution by Number of Funding Instances
  • Table 24.38 Most Active Players: Distribution by Number of Funding Instances
  • Table 24.39 Most Active Players: Distribution by Amount Raised
  • Table 24.40 Funding and Investments: Distribution by Geography (Region)
  • Table 24.41 Funding and Investments: Distribution by Geography (Country)
  • Table 24.42 Global Events Analysis: Cumulative Year-wise Trend, H1 2021 - H1 2024
  • Table 24.43 Global Events Analysis: Distribution by Type of Event
  • Table 24.44 Global Events Analysis: Distribution by Year and Type of Event
  • Table 24.45 Global Events Analysis: Distribution by Event Platform
  • Table 24.46 Global Events Analysis: Distribution by Location of Event (Region)
  • Table 24.47 Global Events Analysis: Distribution by Location of Event (Country)
  • Table 24.48 Most Active Event Organizers: Distribution by Number of Events
  • Table 24.49 Most Active Players: Distribution by Number of Events
  • Table 24.50 Most Active Speakers: Distribution by Number of Events
  • Table 24.51 Distribution by Designation / Qualification of Speakers
  • Table 24.52 Patent Analysis: Distribution by Type of Patent
  • Table 24.53 Patent Analysis: Cumulative Year-wise Trend by Patent Application Year, Pre-2018-2023
  • Table 24.54 Patent Analysis: Cumulative Year-wise Trend by Patent Publication Year, 2019-2023
  • Table 24.55 Patent Analysis: Distribution by Type of Patent and Patent Publication Year, 2019-2023
  • Table 24.56 Patent Analysis: Distribution by Patent Jurisdiction (Region)
  • Table 24.57 Patent Analysis: Distribution by Patent Jurisdiction (Country)
  • Table 24.58 Patent Analysis: Distribution by Patent Publication Year and Type of Applicant
  • Table 24.59 Leading Players: Distribution by Number of Patents
  • Table 24.60 Leading Patent Assignees: Distribution by Number of Patents
  • Table 24.61 Patent Analysis: Distribution by Patent Age
  • Table 24.62 Digital Biomarker Solutions: Patent Valuation
  • Table 24.63 Global Digital Biomarker Solutions Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Table 24.64 Global Digital Biomarker Solutions Market, Forecasted Estimates (2024-2035): Conservative Scenario (USD Million)
  • Table 24.65 Global Digital Biomarker Solutions Market, Forecasted Estimates (2024-2035): Optimistic Scenario (USD Million)
  • Table 24.66 Digital Biomarker Solutions Market for Software / Applications, Historical Trends (2018-2023) (USD Million)
  • Table 24.67 Digital Biomarker Solutions Market: Distribution by Type of Product, 2018, 2024 and 2035
  • Table 24.68 Digital Biomarker Solutions Market for Wearables, Historical Trends (2018-2023) (USD Million)
  • Table 24.69 Digital Biomarker Solutions Market for Software / Applications, Forecasted Estimates (2024-2035) (USD Million)
  • Table 24.70 Digital Biomarker Solutions Market for Sensors, Historical Trends (2018-2023) (USD Million)
  • Table 24.71 Digital Biomarker Solutions Market for Wearables, Forecasted Estimates (2024-2035) (USD Million)
  • Table 24.72 Digital Biomarker Solutions Market for Gaming Solutions, Historical Trends (2018-2023) (USD Million)
  • Table 24.73 Digital Biomarker Solutions Market for Gaming Solutions, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.74 Biomarker Solutions Market: Distribution by Purpose of Solution, 2018, 2024 and 2035
  • Table 24.75 Biomarker Solutions Market for Monitoring, Historical Trends (2018-2023) (USD Million)
  • Table 24.76 Digital Biomarker Solutions Market for Monitoring, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.77 Biomarker Solutions Market for Diagnosis, Historical Trends (2018-2023) (USD Million)
  • Table 24.78 Biomarker Solutions Market for Diagnosis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.79 Digital Biomarker Solutions Market for Early Detection, Historical Trends (2018-2023) (USD Million)
  • Table 24.80 Digital Biomarker Solutions Market for Early Detection, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.81 Biomarker Solutions Market for Predictive Insights, Historical Trends (2018-2023) (USD Million)
  • Table 24.82 Digital Biomarker Solutions Market for Predictive Insights, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.83 Digital Biomarker Solutions Market: Distribution by Type of Biomarker, 2018, 2024 and 2035
  • Table 24.84 Digital Biomarker Solutions Market for Physiological Biomarkers, Historical Trends (2018-2023) (USD Million)
  • Table 24.85 Digital Biomarker Solutions Market for Physiological Biomarkers, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.86 Digital Biomarker Solutions Market for Vocal Biomarkers, Historical Trends (2018-2023) (USD Million)
  • Table 24.87 Digital Biomarker Solutions Market for Vocal Biomarkers, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.88 Digital Biomarker Solutions Market for Cognitive Biomarkers, Historical Trends (2018-2023) (USD Million)
  • Table 24.89 Digital Biomarker Solutions Market for Cognitive Biomarkers, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.90 Digital Biomarker Solutions Market for Idiosyncratic Biomarkers, Historical Trends (2018-2023) (USD Million)
  • Table 24.91 Digital Biomarker Solutions Market for Idiosyncratic Biomarkers, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.92 Digital Biomarker Solutions Market for Other Biomarkers, Historical Trends (2018-2023) (USD Million)
  • Table 24.93 Digital Biomarker Solutions Market for Other Biomarkers, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.94 Digital Biomarker Solutions Market: Distribution by Therapeutic Area, 2018, 2024 and 2035 (USD Million)
  • Table 24.95 Digital Biomarker Solutions Market for Neurological Disorders, Historical Trends (2018-2023) (USD Million)
  • Table 24.96 Digital Biomarker Solutions Market for Neurological Disorders, Forecasted Estimates (2024-2035) Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.97 Digital Biomarker Solutions Market for Mental Health Disorders, Historical Trends (2018-2023) (USD Million)
  • Table 24.98 Digital Biomarker Solutions Market for Mental Health Disorders, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.99 Digital Biomarker Solutions Market for Cardiovascular Disorders, Historical Trends (2018-2023) (USD Million)
  • Table 24.100 Digital Biomarker Solutions Market for Cardiovascular Disorders, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.101 Digital Biomarker Solutions Market for Infectious Diseases, Historical Trends (2018-2023) (USD Million)
  • Table 24.102 Digital Biomarker Solutions Market for Infectious Diseases, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.103 Digital Biomarker Solutions Market for Respiratory Disorders, Historical Trends (2018-2023) (USD Million)
  • Table 24.104 Digital Biomarker Solutions Market for Respiratory Disorders, Historical Trends (2018-2023) (USD Million)
  • Table 24.105 Digital Biomarker Solutions Market for Autoimmune Disorders, Historical Trends (2018-2023) (USD Million)
  • Table 24.106 Digital Biomarker Solutions Market for Autoimmune Disorders, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.107 Digital Biomarker Solutions Market for Substance Abuse Disorders, Historical Trends (2018-2023) (USD Million)
  • Table 24.108 Digital Biomarker Solutions Market for Substance Abuse Disorders, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.109 Digital Biomarker Solutions Market for Other Disorders, Historical Trends (2018-2023) (USD Million)
  • Table 24.110 Digital Biomarker Solutions Market for Other Disorders, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.111 Digital Biomarker Solutions Market: Distribution by Business Model, 2018, 2024 and 2035
  • Table 24.112 Digital Biomarker Solutions Market for B2B Model, Historical Trends (2018-2023) (USD Million)
  • Table 24.113 Digital Biomarker Solutions Market for B2B Model, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.114 Digital Biomarker Solutions Market for B2C Model, Historical Trends (2018-2023) (USD Million)
  • Table 24.115 Digital Biomarker Solutions Market for B2C Model, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.116 Digital Biomarker Solutions Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
  • Table 24.117 Digital Biomarker Solutions Market in North America, Historical Trends (2018-2023) (USD Million)
  • Table 24.118 Digital Biomarker Solutions Market in North America, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.119 Digital Biomarker Solutions Market in Europe, Historical Trends (2018-2023) (USD Million)
  • Table 24.120 Digital Biomarker Solutions Market in Europe, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.121 Digital Biomarker Solutions Market in Asia-Pacific, Historical Trends (2018-2023) (USD Million)
  • Table 24.122 Digital Biomarker Solutions Market in Asia-Pacific, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.123 Digital Biomarker Solutions Market in Middle East and North Africa, Historical Trends (2018-2023) (USD Million)
  • Table 24.124 Digital Biomarker Solutions Market in Middle East and North Africa, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.125 Digital Biomarker Solutions Market in Rest of the World, Historical Trends (2018-2023) (USD Million)
  • Table 24.126 Digital Biomarker Solutions Market in Rest of the World, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)

List of Figures

  • Figure 2.1 Research Methodology: Project Methodology
  • Figure 2.2 Research Methodology: Forecast Methodology
  • Figure 2.3 Research Methodology: Robust Quality Control
  • Figure 2.4 Research Methodology: Key Market Segmentation
  • Figure 3.1 Lessons Learnt from Past Recessions
  • Figure 4.1 Executive Summary: Digital Biomarker Solutions Market Landscape
  • Figure 4.2 Executive Summary: Digital Biomarker Solution Developer Landscape
  • Figure 4.3 Executive Summary: Partnerships and Collaborations
  • Figure 4.4 Executive Summary: Funding and Investments
  • Figure 4.5 Executive Summary: Global Events Analysis
  • Figure 4.6 Executive Summary: Patent Analysis
  • Figure 4.7 Executive Summary: Digital Biomarker Solutions Market Forecast and Opportunity Analysis
  • Figure 5.1 Types of Digital Biomarkers
  • Figure 5.2 Types of Biomarkers / Signals Captured by Digital Biomarker Solutions
  • Figure 5.3 Emerging Focus Areas: Google News
  • Figure 6.1 Digital Biomarker Solutions: Distribution by Type of Product
  • Figure 6.2 Digital Biomarker Solutions: Distribution by Type of Digital Biomarker Solution
  • Figure 6.3 Digital Biomarker Solutions: Distribution by Type of Biomarker
  • Figure 6.4 Digital Biomarker Solutions: Distribution by Status of Development
  • Figure 6.5 Digital Biomarker Solutions: Distribution by Type of Biomarker and Status of Development
  • Figure 6.6 Digital Biomarker Solutions: Distribution by Purpose of Digital Biomarker Solution
  • Figure 6.7 Digital Biomarker Solutions: Distribution by Target Therapeutic Area
  • Figure 6.8 Digital Biomarker Solutions: Distribution by Type of Biomarker and Target Therapeutic Area
  • Figure 6.9 Digital Biomarker Solutions: Distribution by Target Population
  • Figure 6.10 Digital Biomarker Solutions: Distribution by End-user
  • Figure 6.11 Digital Biomarker Solutions: Distribution by Availability of Clinical Validation
  • Figure 6.12 Digital Biomarker Solutions: Distribution of Clinically Validated Solutions by Target Therapeutic Area
  • Figure 6.13 Digital Biomarker Solutions: Distribution by Availability of AI Integration
  • Figure 6.14 Digital Biomarker Solution Developers: Distribution by Year of Establishment
  • Figure 6.15 Digital Biomarker Solution Developers: Distribution by Company Size
  • Figure 6.16 Digital Biomarker Solution Developers: Distribution by Location of Headquarters (Region)
  • Figure 6.17 Digital Biomarker Solution Developers: Distribution by Location of Headquarters (Country)
  • Figure 6.18 Digital Biomarker Solution Developers: Distribution by Company Size and Location of Headquarters
  • Figure 6.19 Most Active Players: Distribution by Number of Digital Biomarker Solutions Developed
  • Figure 7.1 Product Competitiveness Analysis: Digital Biomarker Solutions Developed by Players based in North America
  • Figure 7.2 Product Competitiveness Analysis: Digital Biomarker Solutions Developed by Players based in Europe
  • Figure 7.3 Product Competitiveness Analysis: Digital Biomarker Solutions Developed by Players based in Asia-Pacific and Rest of the World
  • Figure 9.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2019 - 2024
  • Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Figure 9.4 Partnerships and Collaborations: Distribution by Type of Biomarker
  • Figure 9.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Biomarker
  • Figure 9.6 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Figure 9.7 Partnerships and Collaborations: Distribution by Type of Partnership and Therapeutic Area
  • Figure 9.8 Partnerships and Collaborations: Distribution by Type of Partner
  • Figure 9.9 Most Active Players: Distribution by Number of Partnerships
  • Figure 9.10 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
  • Figure 9.11 Partnerships and Collaborations: International and Local Deals
  • Figure 10.1 Funding and Investments: Cumulative Year-wise Trend of Funding Instances, Pre-2018-2024
  • Figure 10.2 Funding and Investments: Cumulative Year-wise Trend of Amount Invested, Pre-2018-2024
  • Figure 10.3 Funding and Investment: Distribution by Type of Funding
  • Figure 10.4 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
  • Figure 10.5 Funding and Investments: Distribution by Type of Biomarker
  • Figure 10.6 Funding and Investments: Distribution by Therapeutic Area
  • Figure 10.7 Leading Investors: Distribution by Number of Funding Instances
  • Figure 10.8 Most Active Players: Distribution by Number of Funding Instances
  • Figure 10.9 Most Active Players: Distribution by Amount Raised
  • Figure 10.10 Funding and Investments: Distribution by Geography (Region)
  • Figure 10.11 Funding and Investments: Distribution by Geography (Country)
  • Figure 11.1 Global Events Analysis: Cumulative Year-wise Trend, H1 2021 - H1 2024
  • Figure 11.2 Global Events Analysis: Distribution by Type of Event
  • Figure 11.3 Global Events Analysis: Distribution by Year and Type of Event
  • Figure 11.4 Global Events Analysis: Distribution by Event Platform
  • Figure 11.5 Global Events Analysis: Distribution by Location of Event (Region)
  • Figure 11.6 Global Events Analysis: Distribution by Location of Event (Country)
  • Figure 11.7 Word Cloud Analysis: Key Focus Areas
  • Figure 11.8 Most Active Event Organizers: Distribution by Number of Events
  • Figure 11.9 Most Active Players: Distribution by Number of Events
  • Figure 11.10 Most Active Speakers: Distribution by Number of Events
  • Figure 11.11 Distribution by Designation / Qualification of Speakers
  • Figure 12.1 Patent Analysis: Distribution by Type of Patent
  • Figure 12.2 Patent Analysis: Cumulative Year-wise Trend by Patent Application Year, Pre-2018-2023
  • Figure 12.3 Patent Analysis: Cumulative Year-wise Trend by Patent Publication Year, 2019-2023
  • Figure 12.4 Patent Analysis: Distribution by Type of Patent and Patent Publication Year, 2019-2023
  • Figure 12.5 Patent Analysis: Distribution by Patent Jurisdiction (Region)
  • Figure 12.6 Patent Analysis: Distribution by Patent Jurisdiction (Country)
  • Figure 12.7 Patent Analysis: Distribution by CPC Symbols
  • Figure 12.8 Patent Analysis: Distribution by Patent Publication Year and Type of Applicant
  • Figure 12.9 Leading Players: Distribution by Number of Patents
  • Figure 12.10 Leading Patent Assignees: Distribution by Number of Patents
  • Figure 12.11 Patent Benchmarking: Distribution of Patent Characteristics (CPC Codes) by Leading Players
  • Figure 12.12 Patent Benchmarking: Distribution of Leading Players by Patent Characteristics (Top CPC Codes)
  • Figure 12.13 Patent Analysis: Distribution by Patent Age
  • Figure 12.14 Digital Biomarker Solutions: Patent Valuation
  • Figure 13.1 Big Pharma Initiatives Related to Digital Biomarker Solutions: Distribution by Type of Initiative
  • Figure 13.2 Big Pharma Initiatives Related to Digital Biomarker Solutions: Heat Map Analysis
  • Figure 13.7 Spider Web Analysis: AbbVie
  • Figure 13.8 Spider Web Analysis: Amgen
  • Figure 13.9 Spider Web Analysis: AstraZeneca
  • Figure 13.10 Spider Web Analysis: Bayer
  • Figure 13.11 Spider Web Analysis: Bristol Myers Squibb
  • Figure 13.12 Spider Web Analysis: Eli Lilly
  • Figure 13.13 Spider Web Analysis: GlaxoSmithKline
  • Figure 13.14 Spider Web Analysis: Johnson & Johnson
  • Figure 13.15 Spider Web Analysis: Merck
  • Figure 13.16 Spider Web Analysis: Novartis
  • Figure 13.17 Spider Web Analysis: Pfizer
  • Figure 13.18 Spider Web Analysis: Roche
  • Figure 13.19 Spider Web Analysis: Sanofi
  • Figure 13.20 . Spider Web Analysis: Takeda Pharmaceuticals
  • Figure 15.1 Global Digital Biomarker Solutions Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 15.2 Global Digital Biomarker Solutions Market, Forecasted Estimates (2024-2035): Conservative Scenario (USD Million)
  • Figure 15.3 Global Digital Biomarker Solutions Market, Forecasted Estimates (2024-2035): Optimistic Scenario (USD Million)
  • Figure 16.1 Digital Biomarker Solutions Market: Distribution by Type of Product, 2018, 2024 and 2035
  • Figure 16.2 Digital Biomarker Solutions Market for Software / Applications: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 16.3 Digital Biomarker Solutions Market for Wearables: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 16.4 Digital Biomarker Solutions Market for Sensors: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 16.5 Digital Biomarker Solutions Market for Gaming Solutions: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 17.1 Digital Biomarker Solutions Market: Distribution by Purpose of Solution, 2018, 2024 and 2035
  • Figure 17.2 Digital Biomarker Solutions Market for Monitoring: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 17.3 Digital Biomarker Solutions Market for Diagnosis: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 17.4 Digital Biomarker Solutions Market for Early Detection: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 17.5 Digital Biomarker Solutions Market for Predictive Insights: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 18.1 Digital Biomarker Solutions Market: Distribution by Type of Biomarker, 2018, 2024 and 2035
  • Figure 18.2 Digital Biomarker Solutions Market for Physiological Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 18.3 Digital Biomarker Solutions Market for Vocal Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 18.4 Digital Biomarker Solutions Market for Cognitive Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 18.5 Digital Biomarker Solutions Market for Idiosyncratic Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 18.6 Digital Biomarker Solutions Market for Other Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 19.1 Digital Biomarker Solutions Market: Distribution by Therapeutic Area, 2018, 2024 and 2035
  • Figure 19.2 Digital Biomarker Solutions Market for Neurological Disorders: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 19.3 Digital Biomarker Solutions Market for Mental Health Disorders: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 19.4 Digital Biomarker Solutions Market for Cardiovascular Disorders: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 19.5 Digital Biomarker Solutions Market for Infectious Diseases: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 19.6 Digital Biomarker Solutions Market for Respiratory Disorders: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 19.7 Digital Biomarker Solutions Market for Autoimmune Disorders: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 19.8 Digital Biomarker Solutions Market for Substance Abuse Disorders: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 19.9 Digital Biomarker Solutions Market for Other Disorders: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 20.1 Digital Biomarker Solutions Market: Distribution by Business Model, 2018, 2024 and 2035
  • Figure 20.2 Digital Biomarker Solutions Market for B2B Model: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 20.3 Digital Biomarker Solutions Market for B2C Model: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 21.1 Digital Biomarker Solutions Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
  • Figure 21.2 Digital Biomarker Solutions Market in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 21.3 Digital Biomarker Solutions Market in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 21.4 Digital Biomarker Solutions Market in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 21.5 Digital Biomarker Solutions Market in Middle East and North Africa: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 21.6 Digital Biomarker Solutions Market in Rest of the World: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 22.1 Concluding Remarks: Digital Biomarker Solutions Market Landscape
  • Figure 22.2 Concluding Remarks: Digital Biomarker Solution Developers Landscape
  • Figure 22.3 Concluding Remarks: Partnerships and Collaborations
  • Figure 22.4 Concluding Remarks: Funding and Investment
  • Figure 22.5 Concluding Remarks: Global Events Analysis
  • Figure 22.6 Concluding Remarks: Patent Analysis
  • Figure 22.7 Concluding Remarks: Market Sizing and Opportunity Analysis (I/II)
  • Figure 22.8 Concluding Remarks: Market Sizing and Opportunity Analysis (II/II)
目次
Product Code: RA100488

The digital biomarkers market is valued at USD 5.55 billion in 2024 growing at a CAGR of 18.5% during the forecast period 2024-2035.

The conventional approach of manually tracking individuals' health data is fraught with numerous challenges, including delays in assessing critical health information, susceptibility to errors, time-consuming and costly processes, and the risk of loss or damage to health records. These factors hinder timely treatment, particularly for the aging population. Alarmingly, it is estimated that 65% of hospital patients and more than 90% of post-acute care patients undergo manual monitoring of vitals and patient-specific parameters every four to eight hours. As a result, telemedicine has gained prominence, leveraging digital tools to provide remote consultations and services. Notably, digital health technologies enable continuous patient monitoring, allowing healthcare practitioners to promptly track baseline changes in individual patients. Additionally, the implementation of continuous monitoring systems has proven to significantly reduce adverse events and hospital readmissions. The burgeoning fields of digital biomarkers and digital therapeutics are integral components of the broader digital health market. Furthermore, according to the World Health Organization, by 2030, one-sixth of the global population will be aged over 60 years. Consequently, proactively detecting symptoms at an early stage is intuitively better than treating patients who are seriously ill due to longer waiting times. Studies have demonstrated that continuous symptom tracking with early intervention has not only led to remarkable improvements in patients' quality of life but has also reduced healthcare costs.

The rising digitalization in the healthcare industry has catalyzed the development of several digital solutions capable of generating, collecting, and tracking medical information via biomarkers in the body. Digital solutions for biomarkers are defined as digital devices, such as smartphones, sensors, and wearable devices, that measure and quantify physiological, behavioral, or biometric data, including blood pressure, emotional health, heart rate, glucose levels, physical activity, respiratory function, and sleep patterns. These advanced solutions enable real-time monitoring of an individual's health, specifically in chronic disease management, encourage proactive participation in wellness activities, and allow personalized healthcare by tailoring treatments based on individual data. With the rising prevalence of chronic diseases, growing emphasis on remote patient monitoring, and continuous advancements in technologies, the digital biomarkers market is poised for growth in the foreseeable future.

Key Market Segments

Type of Product

  • Software / Applications
  • Wearables
  • Sensors
  • Gaming Solutions

Purpose of Solution

  • Diagnosis
  • Early Detection
  • Monitoring
  • Predictive Insights

Type of Biomarker

  • Cognitive Biomarkers
  • Idiosyncratic Biomarkers
  • Physiological Biomarkers
  • Vocal Biomarkers
  • Other Biomarkers

Therapeutic Area

  • Autoimmune Disorders
  • Cardiovascular Disorders
  • Infectious Diseases
  • Mental Health Disorders
  • Neurological Disorders
  • Respiratory Disorders
  • Substance Abuse Disorders
  • Others

Business Model

B2B

B2C

Geographical Regions

  • North America
  • Europe
  • Asia-Pacific
  • Middle East and North Africa (MENA)
  • Rest of the World

Research Coverage:

  • The report studies the digital biomarkers market based on type of product, purpose of solution, type of biomarker, therapeutic area, business model, and key geographical regions
  • The report assesses the potential advantages and obstacles within the market for those involved and offers information on the competitive environment for top players in the market.
  • The report forecasts the revenue of market segments with respect to five major regions
  • The report begins with a general overview of various solutions enabling digital monitoring / detection of biomarkers. It provides information on different types of digital biomarkers, biological signals captured by them, key advantages driving their growing adoption, existing concerns around reliability/credibility of analyzed health data and lack of guidelines. It also outlines the product development and commercialization path for digital biomarkers and highlights recent advances and prevalent trends in this field.
  • It offers a detailed assessment of the current digital biomarker solutions market landscape based on parameters like product type (software/apps, wearables, others), solution type (data collection, data integration), biomarker type (behavioral, cognitive, idiosyncratic, physiological, vocal, others), development status (approved, FDA registered, marketed, R&D), purpose (diagnosis, disease risk management, early detection, monitoring, prognosis, treatment), therapeutic area, target population, end-user type, clinical validation status, and AI integration. It also analyzes digital biomarker developers by year of establishment, company size, headquarters location, business model, and active players.
  • The report provides an insightful analysis of digital biomarker solutions based on developer strength (experience, size, model, number of solutions), product competitiveness (solution type, biomarker type, purpose, clinical validation, AI integration), and development status.
  • It includes elaborate profiles of key digital biomarker developers, featuring company overviews, biomarker portfolios, recent developments, and future outlooks.
  • The report presents a detailed analysis of partnerships between stakeholders from pre-2019 to 2024, based on year, partnership type, biomarker type, therapeutic area, partner type, active players, and regional distribution.
  • It features an analysis of funding/investments raised by digital biomarker developers based on year, funding type, amount, biomarker type, therapeutic area, active players/investors, and regional distribution.
  • The report analyzes global events attended by companies in this industry, based on year, event type, platform, organizer, location, active players, speakers, and designations.
  • It provides an in-depth analysis of digital biomarker patents filed/granted since 2019, based on patent type, publication/application year, jurisdiction, CPC symbols, applicant type, active players, benchmarking, and a patent valuation analysis highlighting leading patents by citations.
  • The report analyzes initiatives by big pharma players related to digital biomarkers, based on parameters like number of clinical trials, collaborations, conferences attended, funding instances, and publications.
  • It identifies and analyzes key drivers, restraints, opportunities, and challenges impacting the growth of the digital biomarkers market.
  • The report provides a detailed market forecast analysis to estimate the existing market size and future opportunity till 2035, based on likely adoption trends and primary validations. It includes three forecast scenarios (conservative, base, optimistic) to account for future uncertainties.
  • It offers detailed projections of the current and future market opportunity across product types (software / apps, wearables, sensors, gaming solutions), solution purposes (diagnosis, early detection, monitoring, predictive insights), biomarker types (cognitive, idiosyncratic, physiological, vocal, others), therapeutic areas, business models (B2B, B2C), and key geographical regions.

Key Benefits of Buying this Report

  • The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
  • Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
  • The report provides stakeholders with a pulse on the digital biomarkers market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Key Market Companies

  • Acculi Labs
  • ActiGraph
  • AliveCor

ATCOR

  • BACtrack
  • Biogen
  • BioSerenity
  • BioSensics
  • Eyenuk
  • Empatica
  • Feel Therapeutics
  • icometrix
  • iMediSync

IXICO

  • Kinsa
  • Koneksa Health
  • Kontigo Care
  • Progentec Diagnostics
  • Quibim
  • Vocalis Health

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Digital Biomarker Solutions Market
  • 1.2. Market Share Insights
  • 1.3. Key Market Insights
  • 1.4. Report Coverage
  • 1.5. Key Questions Answered
  • 1.6. Chapter Outlines

2. RESEARCHMETHODOLOGY

  • 2.1 Chapter Overview
  • 2.2. Research Assumptions
  • 2.3. Project Methodology
  • 2.4. Forecast Methodology
  • 2.5. Robust Quality Control
  • 2.6. Key Market Segmentation
  • 2.7. Key Considerations
    • 2.7.1. Demographics
    • 2.7.2. Economic Factors
    • 2.7.3. Government Regulations
    • 2.7.4. Supply Chain
    • 2.7.5. COVID Impact
    • 2.7.6. Market Access
    • 2.7.7. Healthcare Policies
    • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

  • 3.1 Chapter Overview
  • 3.2. Market Dynamics
    • 3.2.1. Time Period
      • 3.2.1.1. Historical Trends
      • 3.2.1.2. Current and Future Estimates
    • 3.2.2. Currency Coverage and Foreign Exchange Rate
      • 3.2.2.1. Major Currencies Affecting the Market
      • 3.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rates
      • 3.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market
      • 3.2.2.4. Strategies for Mitigating Foreign Exchange Risk
    • 3.2.3. Trade Policies
      • 3.2.3.1. Impact of Trade Barriers on the Market
      • 3.2.3.2. Strategies for Mitigating the Risks Associated with Trade Barriers
    • 3.2.4. Recession
      • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
      • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 3.2.5. Inflation
      • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

  • 5.1 Chapter Overview
  • 5.2. Overview of Digital Biomarkers
    • 5.2.1. Classification of Digital Biomarkers
    • 5.2.2. Types of Biological Signals Captured by Digital Biomarker Solutions
    • 5.2.3. Key Advantages and Limitations
  • 5.3. Product Development and Commercialization Path for Digital Biomarker Solutions
    • 5.3.1. Discovery
    • 5.3.2. Validations and Submissions
    • 5.3.3. Distribution and Marketing
  • 5.4. Recent Advancements related to Digital Biomarker Solutions
  • 5.5. Impact of COVID-19 Pandemic on the Digital Biomarkers Domain
  • 5.6. Prevalent Trends Related to Digital Biomarker Solutions
    • 5.6.1. Emerging Focus Areas

6. MARKET LANDSCAPE

  • 6.1. Chapter Overview
  • 6.2. Digital Biomarker Solutions: Overall Market Landscape
    • 6.2.1. Analysis by Type of Product
    • 6.2.2. Analysis by Type of Digital Biomarker Solution
    • 6.2.3. Analysis by Type of Biomarker
    • 6.2.4. Analysis by Status of Development
    • 6.2.5. Analysis by Type of Biomarker and Status of Development
    • 6.2.6. Analysis by Purpose of Digital Biomarker Solution
    • 6.2.7. Analysis by Target Therapeutic Area
    • 6.2.8. Analysis by Type of Biomarker and Target Therapeutic Area
    • 6.2.9. Analysis by Target Population
    • 6.2.10. Analysis by End-user
    • 6.2.11. Analysis by Availability of Clinical Validation
    • 6.2.12. Analysis by Availability of Clinical Validates Solutions by Target Therapeutic Area
    • 6.2.13. Analysis by Availability of AI Integration
  • 6.3. Digital Biomarker Solutions: Developer Landscape
    • 6.3.1. Analysis by Year of Establishment
    • 6.3.2. Analysis by Company Size
    • 6.3.3 Analysis by Location of Headquarters
    • 6.3.4. Analysis by Company Size and Location of Headquarters
    • 6.3.5. Most Active Players: Analysis by Number of Digital Biomarker Solutions Developed

7. PRODUCT COMPETITIVENESS ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Assumptions and Key Parameters
  • 7.3. Methodology
  • 7.4. Digital Biomarker Solutions: Product Competitiveness Analysis
    • 7.4.1. Digital Biomarker Solutions Developed by Players based in North America
    • 7.4.2. Digital Biomarker Solutions Developed by Players based in Europe
    • 7.4.3. Digital Biomarker Solutions Developed by Players based in Asia-Pacific and Rest of the World

8. COMPANY PROFILES: DIGITAL BIOMARKER SOLUTIONS DEVELOPERS

  • 8.1. Chapter Overview
  • 8.2. Detailed Company Profiles of Leading Digital Biomarker Solutions Developers
    • 8.2.1. BioSensics
      • 8.2.1.1. Company Overview
      • 8.2.1.2. Digital Biomarker Solutions Portfolio
      • 8.2.1.3. Recent Developments and Future Outlook
    • 8.2.2. AliveCor
      • 8.2.2.1. Company Overview
      • 8.2.2.2. Digital Biomarker Solutions Portfolio
      • 8.2.2.3. Recent Developments and Future Outlook
    • 8.2.3. BACtrack
      • 8.2.3.1. Company Overview
      • 8.2.3.2. Digital Biomarker Solutions Portfolio
      • 8.2.3.3. Recent Developments and Future Outlook
    • 8.2.4. Eyenuk
      • 8.2.4.1. Company Overview
      • 8.2.4.2. Digital Biomarker Solutions Portfolio
      • 8.2.4.3. Recent Developments and Future Outlook
    • 8.2.5. Quibim
      • 8.2.5.1. Company Overview
      • 8.2.5.2. Digital Biomarker Solutions Portfolio
      • 8.2.5.3. Recent Developments and Future Outlook
    • 8.2.6. Feel Therapeutics
      • 8.2.6.1. Company Overview
      • 8.2.6.2. Digital Biomarker Solutions Portfolio
      • 8.2.6.3. Recent Developments and Future Outlook
    • 8.2.7. Empatica
      • 8.2.7.1. Company Overview
      • 8.2.7.2. Digital Biomarker Solutions Portfolio
      • 8.2.7.3. Recent Developments and Future Outlook
    • 8.2.8. icometrix
      • 8.2.8.1. Company Overview
      • 8.2.8.2. Digital Biomarker Solutions Portfolio
      • 8.2.8.3. Recent Developments and Future Outlook
    • 8.2.9. Biogen
      • 8.2.9.1. Company Overview
      • 8.2.9.2. Digital Biomarker Solutions Portfolio
      • 8.2.9.3. Recent Developments and Future Outlook
  • 8.3. Short Company Profiles of Other Prominent Developers
    • 8.3.1. Acculi Labs
      • 8.3.1.1. Company Overview
      • 8.3.1.2. Product Portfolio: Digital Biomarker Solutions
    • 8.3.2. IXICO
      • 8.3.2.1. Company Overview
      • 8.3.2.2. Product Portfolio: Digital Biomarker Solutions
    • 8.3.3. Kinsa
      • 8.3.3.1. Company Overview
      • 8.3.3.2. Product Portfolio: Digital Biomarker Solutions
    • 8.3.4. Progentec Diagnostics
      • 8.3.4.1. Company Overview
      • 8.3.4.2. Product Portfolio: Digital Biomarker Solutions
    • 8.3.5. Vocalis Health
      • 8.3.5.1. Company Overview
      • 8.3.5.2. Product Portfolio: Digital Biomarker Solutions
    • 8.3.6. Kontigo Care
      • 8.3.6.1. Company Overview
      • 8.3.6.2. Product Portfolio: Digital Biomarker Solutions
    • 8.3.7. Koneksa Health
      • 8.3.7.1. Company Overview
      • 8.3.7.2. Product Portfolio: Digital Biomarker Solutions
    • 8.3.8. ActiGraph
      • 8.3.8.1. Company Overview
      • 8.3.8.2. Product Portfolio: Digital Biomarker Solutions
    • 8.3.9. BioSerenity
      • 8.3.9.1. Company Overview
      • 8.3.9.2. Product Portfolio: Digital Biomarker Solutions
    • 8.3.10. ATCOR
      • 8.3.10.1. Company Overview
      • 8.3.10.2. Product Portfolio: Digital Biomarker Solutions
    • 8.3.11. iMediSync
      • 8.3.11.1. Company Overview
      • 8.3.11.2. Product Portfolio: Digital Biomarker Solutions

9. PARTNERSHIPS AND COLLABORATIONS

  • 9.1. Chapter Overview
  • 9.2. Partnership Models
  • 9.3. Digital Biomarker Solutions: Partnerships and Collaborations
    • 9.3.1. Analysis by Year of Partnership
    • 9.3.2. Analysis by Type of Partnership
    • 9.3.3. Analysis by Year and Type of Partnership
    • 9.3.4. Analysis by Type of Biomarker
    • 9.3.5. Analysis by Type of Partnership and Type of Biomarker
    • 9.3.6 Analysis by Therapeutic Area
    • 9.3.7. Analysis of Type of Partnership and Therapeutic Area
    • 9.3.8. Analysis by Type of Partner
    • 9.3.9. Most Active Players: Analysis by Number of Partnerships
    • 9.3.10. Analysis by Geography
      • 9.3.10.1. Intracontinental and Intercontinental Deals
      • 9.3.10.2. International and Local Deals

10. FUNDING AND INVESTMENTS

  • 10.1. Chapter Overview
  • 10.2. Funding Models
  • 10.3. Digital Biomarker Solutions: Funding and Investments
    • 10.3.1. Analysis by Year of Investment
    • 10.3.2. Analysis by Amount Invested
    • 10.3.3. Analysis of Funding Instances by Type of Funding
    • 10.3.4. Analysis of Amount Invested by Type of Funding
    • 10.3.5. Analysis of Funding Instances by Type of Biomarker
    • 10.3.6. Analysis of Funding Instances and Amount Invested by Therapeutic Area
    • 10.3.7. Leading Investors: Distribution by Number of Funding Instances
    • 10.3.8. Most Active Players: Distribution by Number of Funding Instances
    • 10.3.9. Most Active Players: Analysis by Amount Raised
    • 10.3.10. Most Active Players: Analysis by Geography

11. GLOBAL EVENTS ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Scope and Methodology
  • 11.3. Digital Biomarker Solutions: Global Events Analysis
    • 11.3.1. Analysis by Year of Event
    • 11.3.2. Analysis by Type of Event
    • 11.3.3. Analysis by Year and Type of Event
    • 11.3.4. Analysis by Event Platform
    • 11.3.5. Analysis by Location of Event
    • 11.3.6. Word Cloud Analysis: Key Focus Areas
    • 11.3.7. Most Active Event Organizers: Analysis by Number of Events
    • 11.3.8. Most Active Players: Analysis by Number of Events
  • 11.4. Global Events: Speaker Analysis
    • 11.4.1. Most Active Speakers: Analysis by Number of Events
    • 11.4.2. Analysis by Designation / Qualification of Speakers
  • 11.5. List of Upcoming Global Events
  • 11.6. Concluding Remarks

12. PATENT ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Scope and Methodology
  • 12.3. Digital Biomarker Solutions: Patent Analysis
    • 12.3.1. Analysis by Patent Application Year
    • 12.3.2. Analysis by Patent Publication Year
    • 12.3.3. Analysis by Type of Patent and Patent Publication Year
    • 12.3.4. Analysis by Patent Jurisdiction
    • 12.3.5. Analysis by CPC Symbols
    • 12.3.6. Analysis by Patent Publication Year and Type of Applicant
    • 12.3.7. Leading Players: Analysis by Number of Patents
    • 12.3.8. Leading Patent Assignees: Analysis by Number of Patents
  • 12.4. Patent Benchmarking Analysis
    • 12.4.1. Analysis By Patent Characteristics
  • 12.5. Patent Valuation
  • 12.6. Leading Patents by Number of Citations

13. BIG PHARMA INITIATIVES

  • 13.1. Chapter Overview
  • 13.2. Methodology and Key Parameters
  • 13.3. Big Pharma Initiatives Related to Digital Biomarker Solutions
    • 13.3.1. Analysis by Type of Initiatives
    • 13.3.2. Heat Map Analysis
  • 13.4. Big Pharma Players: Benchmark Analysis
    • 13.4.1. Spider Web Analysis: AbbVie
    • 13.4.2. Spider Web Analysis: Amgen
    • 13.4.3. Spider Web Analysis: AstraZeneca
    • 13.4.4. Spider Web Analysis: Bayer
    • 13.4.5. Spider Web Analysis: Bristol Myers Squibb
    • 13.4.6. Spider Web Analysis: Eli Lilly
    • 13.4.8. Spider Web Analysis: GlaxoSmithKline
    • 13.4.8. Spider Web Analysis: Johnson & Johnson
    • 13.4.9. Spider Web Analysis: Merck
    • 13.4.10. Spider Web Analysis: Novartis
    • 13.4.11. Spider Web Analysis: Pfizer
    • 13.4.12. Spider Web Analysis: Roche
    • 13.4.13. Spider Web Analysis: Sanofi
    • 13.4.14. Spider Web Analysis: Takeda Pharmaceuticals
  • 13.5. Most Active Players: Distribution by Number of Initiatives

14. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

  • 14.1. Chapter Overview
  • 14.2. Market Drivers
  • 14.3. Market Restraints
  • 14.4. Market Opportunities
  • 14.5. Market Challenges
  • 14.6. Conclusion

15. GLOBAL DIGITAL BIOMARKER SOLUTIONS MARKET

  • 15.1. Chapter Overview
  • 15.2. Assumptions and Methodology
  • 15.3. Global Digital Biomarker Solutions Market, Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 15.3.1. Scenario Analysis
      • 15.3.1.1. Conversative Scenario
      • 15.3.1.2. Optimistic Scenario
  • 15.4. Key Market Segmentation

16. DIGITAL BIOMARKER SOLUTIONS MARKET, BY TYPE OF PRODUCT

  • 16.1. Chapter Overview
  • 16.2. Assumptions and Methodology
  • 16.3. Digital Biomarker Solutions Market: Distribution by Type of Product, 2018, 2024 and 2035
    • 16.3.1. Digital Biomarker Solutions Market for Software / Applications: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 16.3.2. Digital Biomarker Solutions Market for Wearables: Historical Trends Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 16.3.3. Digital Biomarker Solutions Market for Sensors: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 16.3.4. Digital Biomarker Solutions Market for Gaming Solutions: Historical Trends (2018-2023) and Future Estimates (2024-2035)
  • 16.4. Data Triangulation and Validation

17. DIGITAL BIOMARKER SOLUTIONS MARKET, BY PURPOSE OF SOLUTION

  • 17.1. Chapter Overview
  • 17.2. Assumptions and Methodology
  • 17.3. Digital Biomarker Solutions Market: Distribution by Purpose of Solution, 2018, 2024 and 2035
    • 17.3.1. Digital Biomarker Solutions Market for Monitoring: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 17.3.2. Digital Biomarker Solutions Market for Diagnosis: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 17.3.3. Digital Biomarker Solutions Market for Early Detection: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 17.3.4. Digital Biomarker Solutions Market for Predictive Insights: Historical Trends (2018-2023) and Future Estimates (2024-2035)
  • 17.4. Data Triangulation and Validation

18. DIGITAL BIOMARKER SOLUTIONS MARKET, BY TYPE OF BIOMARKER

  • 18.1. Chapter Overview
  • 18.2. Assumptions and Methodology
  • 18.3. Digital Biomarker Solutions Market: Distribution by Type of Biomarker, 2018, 2024 and 2035
    • 18.3.1. Digital Biomarker Solutions Market for Physiological Biomarkers: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 18.3.2. Digital Biomarker Solutions Market for Vocal Biomarkers: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 18.3.3. Digital Biomarker Solutions Market for Cognitive Biomarkers: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 18.3.4. Digital Biomarker Solutions Market for Idiosyncratic Biomarkers: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 18.3.5. Digital Biomarker Solutions Market for Other Biomarkers: Historical Trends (2018-2023) and Future Estimates (2024-2035)
  • 18.4. Data Triangulation and Validation

19. DIGITAL BIOMARKER SOLUTIONS MARKET, BY THERAPEUTIC AREA

  • 19.1. Chapter Overview
  • 19.2. Assumptions and Methodology
  • 19.3. Digital Biomarker Solutions Market: Distribution by Therapeutic Area, 2018, 2024 and 2035
    • 19.3.1. Digital Biomarker Solutions Market for Neurological Disorders: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 19.3.2. Digital Biomarker Solutions Market for Mental Health Disorders: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 19.3.3. Digital Biomarker Solutions Market for Cardiovascular Disorders: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 19.3.4. Digital Biomarker Solutions Market for Infectious Diseases: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 19.3.5. Digital Biomarker Solutions Market for Respiratory Disorders: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 19.3.6. Digital Biomarker Solutions Market for Autoimmune Disorders: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 19.3.7. Digital Biomarker Solutions Market for Substance Abuse Disorders: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 19.3.8. Digital Biomarker Solutions Market for Other Disorders: Historical Trends (2018-2023) and Future Estimates (2024-2035)
  • 19.4. Data Triangulation and Validation

20. DIGITAL BIOMARKER SOLUTIONS MARKET, BY BUSINESS MODEL

  • 20.1. Chapter Overview
  • 20.2. Assumptions and Methodology
  • 20.3. Digital Biomarker Solutions Market: Distribution by Business Model, 2018, 2024 and 2035
    • 20.3.1. Digital Biomarker Solutions Market for B2B Model: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 20.3.2. Digital Biomarker Solutions Market for B2C Model: Historical Trends (2018-2023) and Future Estimates (2024-2035)
  • 20.4. Data Triangulation and Validation

21. DIGITAL BIOMARKER SOLUTIONS MARKET, BY KEY GEOGRAPHICAL REGIONS

  • 21.1. Chapter Overview
  • 21.2. Assumptions and Methodology
  • 21.3. Digital Biomarker Solutions Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
    • 21.3.1. Digital Biomarker Solutions Market in North America: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 21.3.2. Digital Biomarker Solutions Market in Europe: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 21.3.3. Digital Biomarker Solutions Market in Asia-Pacific: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 21.3.4. Digital Biomarker Solutions Market in Middle East and North Africa (MENA): Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 21.3.5. Digital Biomarker Solutions Market in Rest of the World: Historical Trends (2018-2023) and Future Estimates (2024-2035)
  • 21.8. Data Triangulation and Validation

22. CONCLUDING REMARKS

23. EXECUTIVE INSIGHTS

  • 23.1. Chapter Overview
  • 23.2. Acculi Labs
    • 23.2.1. Company Snapshot
    • 23.2.2. Interview Transcript: Rupam Das, Chief Executive Officer
  • 23.3. IXICO
    • 23.3.1. Company Snapshot
    • 23.3.2. Interview Transcript: Rohan Sopp, Business Development Manager
  • 23.4. Tilak Healthcare
    • 23.4.1. Company Snapshot
    • 23.4.2. Interview Transcript: Edouard Gasser, Co-Founder and Chief Executive Officer
  • 23.5. Vocalis Health
    • 23.5.1. Company Snapshot
    • 23.5.2. Interview Transcript: Michael Seggev, Former Chief Commercial Officer

24. APPENDIX 1: TABULATED DATA

25. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION